ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Lantern Pharma Reacquires Irofulven from Allarity Therapeutics contractpharma
July 29, 2021?Allarity Therapeutics A/S and Lantern Pharma Inc. have entered an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full responsibility for future clinical development and commercialization.
Pharma Sources Insight January 2025
